home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Events -> Meetings and Conferences
Search  -  prev / next

Using Commercial Insights in the Out-Licensing of Biopharma Assets

  July 16, 2021  
Xtalks, Online

Positioning a product for successful out-licensing or acquisition is challenging, but the likelihood of achieving an attractive exit can be significantly de-risked by proactive, strategic planning. To maximize an exit before NDA submission, it is critical that sponsors understand the out-licensing environment and how strengths and weaknesses can be leveraged to create a win-win situation.

Register for this webinar to hear an outline of the strategic work that should begin during the earlier phases of development, before licensing or sales discussions begin, and will provide guidance on best practices from a strategic development perspective.

Organized by: Xtalks
Invited Speakers:

Robb Lawrence, SVP of Commercial Strategy Solutions, Camargo

Deadline for Abstracts: -
Registration: Register at Xtalks.
E-mail: jozeph@xtalks.com
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2021 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.